Parr Mcknight Wealth Management Group LLC Has $2.29 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Parr Mcknight Wealth Management Group LLC boosted its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 19.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,155 shares of the company's stock after purchasing an additional 5,107 shares during the quarter. Parr Mcknight Wealth Management Group LLC's holdings in AstraZeneca were worth $2,290,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of AstraZeneca by 189.3% during the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock valued at $1,574,247,000 after acquiring an additional 15,722,197 shares in the last quarter. Marshall Wace LLP purchased a new stake in AstraZeneca during the 4th quarter worth approximately $254,018,000. Boston Partners raised its position in shares of AstraZeneca by 9,985.6% in the 4th quarter. Boston Partners now owns 3,707,479 shares of the company's stock valued at $243,444,000 after purchasing an additional 3,670,719 shares in the last quarter. Alyeska Investment Group L.P. boosted its stake in shares of AstraZeneca by 220.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 3,027,511 shares of the company's stock valued at $198,363,000 after buying an additional 2,083,645 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of AstraZeneca by 815.8% during the fourth quarter. Point72 Asset Management L.P. now owns 1,073,630 shares of the company's stock worth $70,344,000 after buying an additional 1,223,630 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, BNP Paribas started coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, AstraZeneca has a consensus rating of "Moderate Buy" and an average price target of $85.00.

AstraZeneca Stock Performance

NASDAQ AZN traded up $0.99 during trading hours on Thursday, reaching $71.81. The company's stock had a trading volume of 4,045,629 shares, compared to its average volume of 5,272,077. The stock has a market cap of $222.71 billion, a PE ratio of 16.39, a PEG ratio of 1.31 and a beta of 0.37. The business has a 50-day simple moving average of $70.72 and a 200 day simple moving average of $70.71. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.06 EPS. Equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.